AICD Combo Device Implantation — Cost, Top Hospitals & Success Rates | MyMedicPlus

An AICD (Automatic Implantable Cardioverter Defibrillator) combo device — medically termed a CRT-D (Cardiac Resynchronisation Therapy Defibrillator) — is an advanced cardiac implantable electronic device (CIED) that combines two distinct therapeutic technologies: cardiac resynchronisation therapy (CRT, also called biventricular pacing) and an implantable cardioverter defibrillator (ICD). This combination device treats patients who have both a cardiac arrhythmia risk requiring ICD protection and a mechanical dyssynchrony of ventricular contraction requiring resynchronisation.

Cardiac resynchronisation therapy addresses the problem of ventricular dyssynchrony — uncoordinated left ventricular contraction caused by left bundle branch block (LBBB) or other intraventricular conduction delay. In heart failure, LBBB causes the left ventricle's septum and lateral wall to contract at different times (rather than simultaneously), reducing pumping efficiency and worsening left ventricular function. CRT delivers carefully timed simultaneous electrical impulses to the right ventricle and the left ventricular lateral wall (via a coronary sinus lead positioned in a lateral or posterolateral coronary vein), restoring coordinated biventricular contraction and substantially improving cardiac output, left ventricular ejection fraction (LVEF), and exercise capacity.

The ICD component monitors heart rhythm continuously and delivers a shock (150-360 joules) or antitachycardia pacing to terminate life-threatening ventricular arrhythmias (ventricular fibrillation or sustained ventricular tachycardia) that would otherwise be fatal. In patients with severe heart failure and depressed LVEF, both the risk of mechanical deterioration and sudden cardiac death from arrhythmia are simultaneously elevated — making CRT-D the appropriate device when both indications are met.

CRT-D is implanted by specialist electrophysiologists in dedicated electrophysiology labs or cardiac catheterisation laboratories, typically under conscious sedation with local anaesthesia. The procedure is performed at major cardiac centres globally, with leading centres in India, Germany, Singapore, and the United States offering CRT-D implantation at comparable quality but significantly different cost points.

CRT-D is indicated for a specific combination of conditions meeting both CRT and ICD criteria. The primary indication is symptomatic heart failure with reduced ejection fraction (HFrEF) — LVEF of 35% or less — in patients with New York Heart Association (NYHA) functional class II, III, or ambulatory class IV despite optimal guideline-directed medical therapy (GDMT) including beta-blocker, ACE inhibitor or ARB/sacubitril-valsartan, and mineralocorticoid receptor antagonist, who also have significant ventricular dyssynchrony demonstrated by wide QRS complex (LBBB morphology with QRS duration above 130 ms, or non-LBBB morphology with QRS above 150 ms).

Independently, ICD indication exists for primary prevention of sudden cardiac death in patients with LVEF 35% or below on GDMT for at least 3 months after treatment of any reversible cause (such as revascularisation for ischaemic heart failure), and for secondary prevention in patients who have survived ventricular fibrillation or sustained ventricular tachycardia. When both CRT criteria and ICD criteria are independently met in the same patient, a CRT-D (rather than separate CRT-P pacemaker plus separate ICD) is the appropriate combined device. Non-ischaemic dilated cardiomyopathy (DCM), ischaemic cardiomyopathy post-MI, and cardiac sarcoidosis are the most common underlying diagnoses in patients receiving CRT-D.

Ideal CRT-D candidates have all of the following: LVEF 35% or below; symptomatic heart failure (NYHA II-III) despite optimised GDMT for at least 3 months; sinus rhythm with LBBB and QRS above 130 ms (or QRS above 150 ms for non-LBBB patterns); and either an ICD indication for primary or secondary prevention of sudden cardiac death, or already an ICD recipient whose clinical course now additionally meets CRT criteria. Life expectancy of at least 1 year with good functional status is required — patients with NYHA class IV requiring inotropes or mechanical circulatory support are not typical CRT-D candidates unless bridging to transplantation.

Patients in atrial fibrillation can receive CRT-D but response rates are lower unless adequate biventricular pacing is achieved (typically requiring AV node ablation to ensure all beats are biventricular paced). Very short QRS duration (below 130 ms) is a contraindication to CRT — ECHO-guided assessments of dyssynchrony without QRS prolongation have not improved patient selection beyond ECG criteria in clinical trials. Renal function, coagulation status, and complete blood count are assessed pre-operatively. The target subclavian vein must be patent for transvenous lead access — venography or ultrasound assessment guides planning when prior devices or procedures suggest venous obstruction.

CRT-D devices are manufactured by all major cardiac device companies — Medtronic (Viva XT, Claria), Abbott (Quadra Assura MP), Boston Scientific (COGNIS, RESONATE), and Biotronik (Rivacor 7 HF). All deliver equivalent core therapy; differentiation lies in remote monitoring capability (Medtronic CareLink, Abbott Merlin@home, Boston Scientific LATITUDE), device longevity (6-9 years), shock energy, and left ventricular lead features.

The implantation procedure begins with fluoroscopy-guided venous access via the subclavian or axillary vein on the left side (usually). Three leads are advanced: a right ventricular defibrillator lead (with shock coils) positioned at the right ventricular apex or septum; a right atrial lead at the right atrial appendage for sensing and AV synchrony; and a left ventricular lead advanced through the coronary sinus into a lateral or posterolateral coronary vein for LV pacing. The left ventricular lead placement is the most technically challenging element — coronary sinus venography identifies the venous anatomy and the optimal target vein. Quadripolar LV leads (Abbott Quartet, Medtronic Attain Performa) with 4 pacing electrodes allow post-implant programming optimisation to maximise capture while avoiding phrenic nerve stimulation. The generator is placed in a subcutaneous or submuscular pocket below the left clavicle. Defibrillation threshold testing is performed in most patients to confirm adequate shock energy.

The clinical evidence base for CRT-D in appropriate patients is among the strongest in interventional cardiology. The CARE-HF trial demonstrated that CRT (in patients with LBBB and low EF) reduced all-cause mortality by 36% and heart failure hospitalisation by 52% over 29 months, with substantial improvement in quality of life, exercise capacity, and LVEF (mean improvement 3.7 percentage points). The COMPANION trial comparing CRT-P (pacemaker only) to CRT-D showed that the ICD component further reduces mortality beyond CRT alone. MADIT-CRT demonstrated 34% reduction in death and worsening heart failure with CRT-D over ICD alone in NYHA I-II heart failure patients with LBBB — establishing CRT-D benefit in milder heart failure.

Clinical response to CRT — defined as an increase in LVEF above 10 percentage points, NYHA class improvement, and reduction in left ventricular end-systolic volume by more than 15% — is called 'super-response' and occurs in approximately 20-30% of patients, who may experience near-normalisation of cardiac function. Overall, 65-75% of appropriately selected patients exhibit a meaningful clinical and echocardiographic response to CRT. ICD protection simultaneously conferred by the device reduces sudden cardiac death risk by 23-25% in patients with LVEF 35% or below compared to medical therapy alone.

CRT-D implantation carries procedural and long-term device-related risks. Procedural risks include: pneumothorax from subclavian vein access (0.5-2%), coronary sinus dissection or perforation during LV lead placement (1-3%), lead dislodgement requiring repositioning (LV lead 5-10% in early series, now 2-4% with improved leads), pocket haematoma (2-5%), and device-related infection (1-2% requiring device extraction). Coronary sinus lead placement failure — inability to obtain adequate LV capture from a stable position without phrenic nerve stimulation — occurs in 5-8% of patients and may necessitate surgical epicardial LV lead placement.

Long-term risks include: inappropriate ICD shocks from inappropriate detection of fast supraventricular tachycardia as ventricular fibrillation (5-10% annually without programming optimisation); device infection requiring complete device extraction and reimplantation (1% per year cumulative, higher in diabetic and immunocompromised patients); lead fracture or insulation failure requiring lead revision; and generator end-of-life requiring elective generator change every 6-9 years. Loss of CRT — biventricular pacing percentage falling below 98% due to frequent ectopy or atrial fibrillation — substantially reduces CRT benefit and requires rate or rhythm control to restore high biventricular pacing percentage.

Post-implant, patients are hospitalised for 1-2 days with telemetry monitoring for lead dislodgement, arrhythmia detection, and wound inspection. A post-implant chest X-ray confirms lead position. Arm movement on the implant side is restricted for 4-6 weeks to prevent lead dislodgement during the healing process while fibrous lead attachment forms. Driving is typically restricted for 6 weeks post-implant (or longer if the indication was secondary prevention of ventricular arrhythmia) — specific national DVLA/DVSA rules apply by indication.

Device follow-up occurs at 6 weeks post-implant for wound check, device interrogation, and optimisation of AV and VV delay intervals to maximise CRT response (guided by echo-optimisation or algorithms such as SonR or SmartDelay). Thereafter, device interrogation occurs every 6 months in clinic, with remote monitoring transmissions reviewed between visits. Echocardiogram at 6 months post-implant assesses LVEF response and LV remodelling. Patients with adequate CRT response (LV EF improvement, volume reduction) continue GDMT medical therapy with potential for gradual medication optimisation as cardiac function improves.

CRT-D implantation in the United States costs $80,000-$150,000 including the device, hospitalisation, and electrophysiology team fees. The device alone (generator plus three leads) costs $25,000-$45,000 at US list prices. In the United Kingdom under private care, the complete episode costs £30,000-£60,000. CRT-D is NHS-funded when criteria are met, with waiting times of several months at many centres.

At leading cardiac centres in India — Fortis Escorts Heart Institute Delhi, Narayana Health Bangalore, Asian Heart Institute Mumbai, Apollo Hospitals Chennai — CRT-D implantation including the device, electrophysiology procedure, and hospitalisation costs $15,000-$30,000 — saving $50,000-$120,000 compared to US rates. The device itself (original Medtronic or Abbott) is used; device costs are globally traded. Thailand (Bumrungrad, BNH Hospital) charges $20,000-$40,000. Indian electrophysiologists at major cardiac centres are trained at international EP fellowship programmes and publish in peer-reviewed journals. Patients should confirm that the specific CRT-D device model implanted will have remote monitoring accessible and serviceable in their home country.

For patients meeting ICD criteria but not CRT criteria (QRS below 130 ms, no significant dyssynchrony), a standalone ICD without biventricular pacing is the appropriate device choice. For patients meeting CRT criteria but not ICD criteria (LVEF 35% or below, wide LBBB, but no sudden death risk indication — for example NYHA class IV requiring transplant consideration), a CRT-P (pacemaker without defibrillator) is less costly and avoids ICD-related risks while providing resynchronisation benefit.

His bundle pacing and left bundle branch area pacing (LBBP) are emerging physiological alternatives to conventional biventricular CRT, delivering pacing to the native conduction system to produce synchronous ventricular activation without the need for a coronary sinus LV lead — potentially avoiding LV lead failure and placement difficulty. Early data show comparable or superior QRS narrowing and haemodynamic improvement, and selected electrophysiology centres are increasingly implanting LBBP-D (left bundle branch pacing defibrillator) devices in appropriate patients. Heart transplantation remains the definitive treatment for refractory end-stage heart failure in appropriate patients below 70 years without contraindications, and left ventricular assist devices (LVAD, HeartMate 3) provide mechanical circulatory support as bridge to transplantation or destination therapy for patients not eligible for transplantation.